Janssen, a pharmaceutical subsidiary of Johnson & Johnson, has announced plans to pursue a pediatric indication for its best-selling blood thinner, Xarelto (rivaroxaban).
Teresa McNulty
Advertisement
Articles by Teresa McNulty
Advertisement
Latest Updated Articles
New Phase 3 data advances pursuit of pediatric indication for XareltoPublished: July 16th 2019 | Updated:
Advertisement
Advertisement
